EZR and invasive breast carcinoma: As the decrease of ER is a hallmark of acquired endocrine resistance that is associated with BrCa recurrence (Nardone et al., 2015; Chi et al., 2019), our study further indicated that Ezrin could negatively regulate ER expression and activation which supports our above hypothesis.